By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received a second indication approval from China’s National Medical Products Administration (NMPA) for its Denosu biosimilar, referencing Amgen’s Xgeva (denosumab). The RANKL inhibitor is now approved for patients with bone metastases from solid tumors or multiple myeloma to delay or reduce skeletal-related events.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) |
| Product | Denosu (denosumab biosimilar) |
| Reference Product | Amgen’s Xgeva (denosumab) |
| Regulatory Agency | National Medical Products Administration (NMPA), China |
| New Indication | Bone metastases from solid tumors and multiple myeloma |
| Therapeutic Benefit | Delay/reduce skeletal-related events (pathologic fractures, spinal cord compression, bone radiotherapy, bone surgery) |
| Previous Approval | March 2025 for unresectable giant cell tumor of bone |
Clinical Indication Details
- Patient Population: Adults and skeletally mature adolescents with bone metastases from solid tumors or multiple myeloma
- Skeletal-Related Events Prevention: Pathologic fractures, spinal cord compression, bone radiotherapy, or bone surgery
- Mechanism of Action: RANKL inhibitor that reduces osteoclast-mediated bone destruction
- Dosing Regimen: Standard denosumab dosing protocol for bone metastasis indication
- Safety Profile: Consistent with reference product Xgeva based on biosimilarity studies
Strategic Market Positioning
The expanded indication significantly broadens Denosu’s addressable market in China, where the burden of cancer-related bone complications continues to grow with aging demographics and improved cancer survival rates. The approval positions Mabwell as a key domestic supplier of critical oncology supportive care medications.
Industry analysts note that biosimilars of high-value biologics like denosumab represent a strategic priority for Chinese biopharmaceutical companies seeking to capture market share from multinational originators while supporting national healthcare cost containment objectives.
Commercial Impact & Market Dynamics
- Market Expansion: Second indication substantially increases total addressable patient population
- Pricing Advantage: Expected to offer significant cost savings compared to originator Xgeva
- Healthcare System Benefits: Supports China’s ongoing efforts to improve access to essential oncology medications
- Competitive Landscape: Positions Mabwell against other domestic biosimilar developers and Amgen’s established franchise
- Revenue Potential: Bone metastasis indication represents larger commercial opportunity than initial giant cell tumor indication
Forward-Looking Statements
This brief contains forward-looking statements regarding Mabwell’s commercial prospects and market positioning. Actual results may differ due to competitive dynamics, pricing pressures, and evolving regulatory requirements for biosimilars in China.-Fineline Info & Tech